Welcome to our dedicated page for AKANDA news (Ticker: AKAN), a resource for investors and traders seeking the latest updates and insights on AKANDA stock.
Akanda Corp. reports corporate and operating developments across its public-company structure, including updates involving First Towers & Fiber Corp., its wholly owned telecommunications infrastructure subsidiary in Mexico. Recent company news centers on dark fiber network leasing, long-term fiber capacity agreements, and expansion of network coverage in Central Mexico.
Akanda news also includes shareholder voting matters, special meeting adjournments, reverse stock splits, convertible-note financing, and other capital-structure actions. The company's historical cannabis operations have included cultivation, manufacturing, and distribution of medical cannabis products, while current updates also reference operating and financial results and clinical or regulatory disclosure categories.
Akanda Corp. (NASDAQ: AKAN) and Tetra Bio-Pharma (TSX: TBP, OTCQB: TBPMF) have formed a strategic partnership where Akanda will supply Tetra with pharmaceutical-grade cannabis flower in microdose caps for their QIXLEEF™ products. This collaboration allows Akanda to enter the cannabis drug development market and secures Tetra a reliable source of high-quality ingredients for FDA clinical trials. The total addressable market for QIXLEEF™ is projected to be $1.7 billion by 2028. The partnership enables Akanda to enhance its CDMO capabilities and support Tetra's commercialization efforts.
Akanda Corp. (NASDAQ: AKAN) and Tetra Bio-Pharma (TSX: TBP, OTCQB: TBPMF) announced a strategic supply agreement where Akanda will provide pharmaceutical-grade cannabis for Tetra’s QIXLEEF™ product. This partnership allows Akanda to enter the cannabinoid drug market and supports Tetra's FDA clinical trials for cancer pain management. The companies estimate a total addressable market of nearly $1.7 billion by 2028, with the supply commencing in Q3 2022 and potentially reaching over 10 metric tonnes annually.
Akanda Corp. (NASDAQ: AKAN) has announced a strategic partnership between its UK subsidiary, CanMart Ltd., Phlo Connect, and Cellen Life Sciences to launch a fully digital dispensing model for medical cannabis. This collaboration aims to enhance access to high-quality cannabis products for UK patients, minimizing prescription and delivery friction. The digital dispensing solution is now live, enabling patients to receive medications conveniently at home. CEO Tej Virk expressed confidence in expanding access to medical cannabis, addressing patient needs in the growing UK market.
Akanda Corp. (NASDAQ: AKAN) has successfully acquired Holigen Limited from Flowr Corporation (TSXV: FLWR, OTC: FLWPF) for approximately US$3.0 million in cash, 1.9 million common shares, and the assumption of US$4.3 million in non-recourse debt. This acquisition enhances Akanda's operational capacity and expands its seed-to-patient model in the EMEA region, aimed at meeting the increasing demand for medical cannabis. CEO Tej Virk stated that the acquisition positions Akanda as a leader in emerging cannabis markets, including adult-use opportunities.
Akanda Corp has announced an agreement to acquire Holigen Limited from Flowr Corporation for US$3 million in cash, plus shares and debt assumption. This acquisition will enhance Akanda’s operations in Europe, providing immediate EU GMP certification and expanding its product offerings with a high-quality genetics library. The deal aims to accelerate Akanda's seed-to-patient model, satisfying the growing demand for medical cannabis in emerging markets, and is expected to close in Q2 2022.
Akanda Corp. has completed its initial public offering (IPO) of 4,000,000 common shares at $4.00 each, raising a total of $16,000,000 in gross proceeds. The company intends to utilize these funds for property, plant, and equipment, operations, working capital, and general corporate purposes. Its shares are listed on The Nasdaq Capital Market under the ticker symbol 'AKAN,' effective March 15, 2022. Boustead Securities, LLC acted as the lead underwriter for this offering.
Akanda Corp. (NASDAQ: AKAN) has begun trading its common shares on The Nasdaq Capital Market, closing its first trading day at $10.50, above the offering price. The company priced its public offering of 4 million shares at $4.00 per share on March 14, 2022, raising $16 million in gross proceeds. Boustead Securities, LLC acted as the lead underwriter for this offering. Akanda focuses on the medical cannabis sector, promoting access to high-quality products through its operations in Lesotho and the UK.
Akanda Corp (NASDAQ: AKAN) has commenced trading on The Nasdaq Capital Market, making it the first UK cannabis company with African operations to be listed. CEO Tej Virk highlighted the significance of this milestone for both the company and the industry, aiming to enhance patient access across the UK and Europe. The company plans to establish a 'seed-to-patient' model, emphasizing ethical business practices and community impact in Lesotho. Akanda aims to provide high-quality cannabis products and improve lives through increased access.